Involvement of miR-30c in resistance to doxorubicin by regulating YWHAZ in breast cancer cells

Brazilian Journal of Medical and Biological Research

Volumn 47, Issue 1, 2014, Pages 60-69

  Fang, Y ^a   Shen, H ^a   Cao, Y ^a   Li, H ^a   Qin, R ^a   Chen, Q ^a   Long, L ^a   Zhu, X L ^a   Xie, C J ^a   Xu, W L ^a  

^a JIANGSU UNIVERSITY   (China)

Author keywords

Breast cancer cells; Doxorubicin resistance; miR 30c; YWHAZ

Indexed keywords

DOXORUBICIN; MESSENGER RNA; MICRORNA; MIR 30C; MITOGEN ACTIVATED PROTEIN KINASE P38; POLYPEPTIDE; SMALL INTERFERING RNA; TRYPTOPHAN HYDROXYLASE; TYROSINE 3 MONOOXYGENASE; TYROSINE 3 MONOOXYGENASE TRYPTOPHAN 5 MONOOXYGENASE ACTIVATION PROTEIN ZETA POLYPEPTIDE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; MIRN30 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS ASSAY; ARTICLE; BREAST CANCER; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; WESTERN BLOTTING; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IC50; MCF 7 CELL LINE; PHYSIOLOGY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITORY CONCENTRATION 50; MCF-7 CELLS; MICE; MICRORNAS; TRYPTOPHAN HYDROXYLASE; TYROSINE 3-MONOOXYGENASE;

EID: 84892999527     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/1414-431X20133324     Document Type: Article

References (37)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29, doi: 10.3322/caac.20138.
2. Sorlie T, Perou CM, Fan C, Geisler S, Aas T, Nobel A, et al. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Mol Cancer Ther 2006; 5: 2914-2918, doi: 10.1158/1535-7163.MCT-06-0126.
3. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-297, doi: 10.1016/S0092-8674(04)00045-5.
4. Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z, et al. MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 2008; 7: 1-9, doi: 10.1158/1535-7163.MCT-07-0573.
5. Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, et al. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Biochem Pharmacol 2008; 76: 582-588, doi: 10.1016/j.bcp.2008.06.007.
6. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF, et al. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008; 7: 2152-2159, doi: 10.1158/1535-7163.MCT-08-0021.
7. Poudel S, Song J, Jin EJ, Song K. Sulfuretin-induced miR-30C selectively downregulates cyclin D1 and D2 and triggers cell death in human cancer cell lines. Biochem Biophys Res Commun 2013; 431: 572-578, doi: 10.1016/j.bbrc.2013.01.012.
8. Bockhorn J, Yee K, Chang YF, Prat A, Huo D, Nwachukwu C, et al. MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast Cancer Res Treat 2013; 137: 373-382, doi: 10.1007/s10549-012-2346-4.
9. Wu T, Zhou H, Hong Y, Li J, Jiang X, Huang H. miR-30 family members negatively regulate osteoblast differentiation. J Biol Chem 2012; 287: 7503-7511, doi: 10.1074/jbc. M111.292722.
10. Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, et al. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun 2013; 4: 1393, doi: 10.1038/ncomms2393.
11. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, et al. Real-time quantification of microRNAs by stemloop RT-PCR. Nucleic Acids Res 2005; 33: e179, doi: 10.1093/nar/gni178.
12. Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, Li Y, et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 2010; 16: 214-218, doi: 10.1038/nm.2090.
13. Brozovic A, Fritz G, Christmann M, Zisowsky J, Jaehde U, Osmak M, et al. Long-term activation of SAPK/JNK, p38 kinase and fas-L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistance. Int J Cancer 2004; 112: 974-985, doi: 10.1002/ijc.20522.
14. Zhang Y, Huang Y, Rishi AK, Sheikh MS, Shroot B, Reichert U, et al. Activation of the p38 and JNK/SAPK mitogenactivated protein kinase pathways during apoptosis is mediated by a novel retinoid. Exp Cell Res 1999; 247: 233-240, doi: 10.1006/excr.1998.4350.
15. Choi JE, Hur W, Jung CK, Piao LS, Lyoo K, Hong SW, et al. Silencing of 14-3-3zeta over-expression in hepatocellular carcinoma inhibits tumor growth and enhances chemosensitivity to cis-diammined dichloridoplatium. Cancer Lett 2011; 303: 99-107, doi: 10.1016/j.canlet.2011.01.015.
16. Naumov GN, Townson JL, MacDonald IC, Wilson SM, Bramwell VH, Groom AC, et al. Ineffectiveness of doxorubicin treatment on solitary dormant mammary carcinoma cells or late-developing metastases. Breast Cancer Res Treat 2003; 82: 199-206, doi: 10.1023/B:BREA.0000004377.12288.3c.
17. Rivera E, Gomez H. Chemotherapy resistance in metastatic breast cancer: the evolving role of ixabepilone. Breast Cancer Res 2010; 12 (Suppl 2): S2, doi: 10.1186/bcr2573.
18. Lee CH, Kuo WH, Lin CC, Oyang YJ, Huang HC, Juan HF. MicroRNA-regulated protein-protein interaction networks and their functions in breast cancer. Int J Mol Sci 2013; 14: 11560-11606, doi: 10.3390/ijms140611560.
19. Gao J, Li L, Wu M, Liu M, Xie X, Guo J, et al. MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1. PLoS One 2013; 8: e65138, doi: 10.1371/journal.pone.0065138.
20. Yang G, Wu D, Zhu J, Jiang O, Shi Q, Tian J, et al. Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1. Oncol Rep 2013; 30: 877-889.
21. Bisso A, Faleschini M, Zampa F, Capaci V, De Santa J, Santarpia L, et al. Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer. Cell Cycle 2013; 12: 1679-1687, doi: 10.4161/cc.24757.
22. Nassirpour R, Mehta PP, Baxi SM, Yin MJ. miR-221 promotes tumorigenesis in human triple negative breast cancer cells. PLoS One 2013; 8: e62170, doi: 10.1371/journal.pone.0062170.
23. Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, et al. EGFR and MET receptor tyrosine kinasealtered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 2012; 18: 74-82, doi: 10.1038/nm.2577.
24. Li XH, Ha CT, Fu D, Xiao M. Micro-RNA30c negatively regulates REDD1 expression in human hematopoietic and osteoblast cells after gamma-irradiation. PLoS One 2012; 7: e48700, doi: 10.1371/journal.pone.0048700.
25. Marchand A, Proust C, Morange PE, Lompre AM, Tregouet DA. miR-421 and miR-30c inhibit SERPINE 1 gene expression in human endothelial cells. PLoS One 2012; 7: e44532, doi: 10.1371/journal.pone.0044532.
26. Chen JP, Liu Y, Hu ZB, Shen HB. [Single nucleotide polymorphism in flanking region of miR-30c influences the maturing process of miR-30c in lung carcinoma]. Zhonghua Zhong Liu Za Zhi 2012; 34: 664-668.
27. Rodriguez-Gonzalez FG, Sieuwerts AM, Smid M, Look MP, Meijer-van Gelder ME, de Weerd V, et al. MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat 2011; 127: 43-51, doi: 10.1007/s10549-010-0940-x.
28. Mu YP, Su XL. Polymorphism in pre-miR-30c contributes to gastric cancer risk in a Chinese population. Med Oncol 2012; 29: 1723-1732, doi: 10.1007/s12032-011-0115-6.
29. Baguley BC. Tumor stem cell niches: a new functional framework for the action of anticancer drugs. Recent Pat Anticancer Drug Discov 2006; 1: 121-127, doi: 10.2174/157489206775246494.
30. Tzivion G, Gupta VS, Kaplun L, Balan V. 14-3-3 Proteins as potential oncogenes. Semin Cancer Biol 2006; 16: 203-213, doi: 10.1016/j.semcancer.2006.03.004.
31. Ando K, Ozaki T, Yamamoto H, Furuya K, Hosoda M, Hayashi S, et al. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 2004; 279: 25549-25561, doi: 10.1074/jbc.M314182200.
32. Costa RH. FoxM1 dances with mitosis. Nat Cell Biol 2005; 7: 108-110, doi: 10.1038/ncb0205-108.
33. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008; 9: 102-114, doi: 10.1038/nrg2290.
34. McPherson RA, Harding A, Roy S, Lane A, Hancock JF. Interactions of c-Raf-1 with phosphatidylserine and 14-3-3. Oncogene 1999; 18: 3862-3869, doi: 10.1038/sj.onc.1202730.
35. Mansouri A, Ridgway LD, Korapati AL, Zhang Q, Tian L, Wang Y, et al. Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells. J Biol Chem 2003; 278: 19245-19256, doi: 10.1074/jbc. M208134200.
36. Weir NM, Selvendiran K, Kutala VK, Tong L, Vishwanath S, Rajaram M, et al. Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol Ther 2007; 6: 178-184, doi: 10.4161/cbt.6.2.3577.
37. Min S, Liang X, Zhang M, Zhang Y, Mei S, Liu J, et al. Multiple tumor-associated microRNAs modulate the survival and longevity of dendritic cells by targeting YWHAZ and Bcl2 signaling pathways. J Immunol 2013; 190: 2437-2446, doi: 10.4049/jimmunol.1202282.